Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of six distinct compounds: - **Caffeine** is a central nervous system stimulant commonly found in coffee and other beverages. - **Bupropion** is an atypical antidepressant and smoking cessation aid that acts as a norepinephrine-dopamine reuptake inhibitor. - **Rosiglitazone** is an antidiabetic agent in the thiazolidinedione class that improves insulin sensitivity by acting as a peroxisome proliferator-activated receptor gamma (PPARγ) agonist. - **Omeprazole** is a proton pump inhibitor used to reduce stomach acid production by irreversibly inhibiting the H+/K+-ATPase enzyme system on gastric parietal cells[1][2][3][4][5][8]. - **Midazolam** is a benzodiazepine used for sedation and anesthesia; it enhances the effect of GABA at the GABAA receptor[6]. - **Bilirubin** is not typically considered a drug but rather an endogenous breakdown product of heme metabolism; it can be measured clinically as an indicator of liver function. This combination does not represent any known marketed pharmaceutical product or therapy. Each component has distinct mechanisms and indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on caffeine + bupropion + rosiglitazone + omeprazole + midazolam + bilirubin.